A randomized, placebo controlled, phase Ib trial to evaluate the safety and pharmacokinetics of NOV-205 [Novelos Therapeutics] in chronic viral hepatitis C subjects (genotype 1) who have failed treatment with pegylated interferon [peginterferon] plus ribavirin

Trial Profile

A randomized, placebo controlled, phase Ib trial to evaluate the safety and pharmacokinetics of NOV-205 [Novelos Therapeutics] in chronic viral hepatitis C subjects (genotype 1) who have failed treatment with pegylated interferon [peginterferon] plus ribavirin

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2014

At a glance

  • Drugs Glutathione/inosine (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 11 Feb 2014 Novelos Therapeutics now known as Cellectar Biosciences
    • 14 Dec 2007 Status changed from recruiting to completed according to a Novelos Therapeutics media release.
    • 02 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top